Company Encyclopedia
View More
name
Merus BV
MRUS.US
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co.
1.946 T
MRUS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking65/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-51.57%E
    • Profit Margin-673.31%E
    • Gross Margin17.74%D
  • Growth ScoreB
    • Revenue YoY57.54%A
    • Net Profit YoY-55.85%D
    • Total Assets YoY7.05%B
    • Net Assets YoY10.19%B
  • Cash ScoreB
    • Cash Flow Margin-14.85%D
    • OCF YoY57.54%A
  • Operating ScoreE
    • Turnover0.06E
  • Debt ScoreA
    • Gearing Ratio14.30%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Merus N.V. $MRUS Shares Acquired by Ensign Peak Advisors Inc

    Ensign Peak Advisors Inc increased its stake in Merus N.V. by 72.4% in Q2, owning 11,550 shares worth $608,000. Other institutional investors also increased their holdings. Analysts have mixed ratings on Merus, with a consensus target price of $93.56. Merus stock opened at $96.08, with a market cap of $7.29 billion. Insider VP Harry Shuman sold 8,300 shares, reducing his ownership by 43%.

    Market Beat·
    US
    MRUS
    +0.10%
    Market Beat·
    US
    MRUS
    +0.10%

    VP Shuman Sells 8,300 ($796.1K) Of Merus NV [MRUS]

    VP Shuman of Merus NV sold 8,300 shares for $796,136, as disclosed in a Form 4 filed with the SEC. The transaction involved exercising shares at $19.68 and selling them at $95.92. Ending holdings are 11,002 shares directly. Various shares were exercised years before expiration. The Washington Service offers insider trading analysis and data services.

    Reuters·
    US
    MRUS
    +0.10%
    Reuters·
    US
    MRUS
    +0.10%

    Rhenman & Partners Asset Management AB Buys 41,500 Shares of Merus N.V. $MRUS

    Rhenman & Partners Asset Management AB increased its stake in Merus N.V. by 55.7% in Q2, owning 116,000 shares worth $6.1 million. Other investors also increased their holdings. Analysts have mixed ratings on Merus, with a consensus 'Hold' rating and a $93.56 price target. Merus shares are trading at $96.02, with a market cap of $7.28 billion. The company develops antibody therapeutics, including Zenocutuzumab, in clinical trials for cancer treatment.

    Market Beat·
    US
    MRUS
    +0.10%
    Market Beat·
    US
    MRUS
    +0.10%

    17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-MRUS, ACLS, VECO, and CLCO

    Monteverde & Associates PC is investigating mergers involving Merus N.V., Axcelis Technologies, Veeco Instruments, and Cool Company Ltd. Shareholders are urged to act before the tender offer expires. The firm has a successful track record in recovering money for shareholders and is recognized as a top firm in securities class action services.

    prnewswire·
    US
    MRUS
    +0.10%
    US
    VECO
    +0.13%
    US
    CLCO
    0.00%
    prnewswire·
    US
    MRUS
    +0.10%
    US
    VECO
    +0.13%
    US
    CLCO
    0.00%

    Merus (MRUS): Assessing Valuation After Strong Share Price Momentum and Pipeline Advances

    Merus (MRUS) has seen a strong share price increase, with a 126% year-to-date return, driven by optimism around its clinical pipeline. The stock's price-to-book ratio of 9.4x suggests it is overvalued compared to peers and the biotech sector average. Investors are debating if the current price reflects future growth potential or if there's room for upside. Risks include potential setbacks in clinical trials or regulatory delays. The analysis is general and not financial advice.

    Simplywall·
    US
    MRUS
    +0.10%
    Simplywall·
    US
    MRUS
    +0.10%
    © 2025 Longbridge｜Disclaimer